About KaloCyte
KaloCyte is a company based in St. Louis (United States) founded in 2016 by Dipanjan Pan, Philip Spinella, and Allan Doctor. KaloCyte has raised $1.1 million across 6 funding rounds from investors including HHS, NYBC Ventures and Maryland Momentum Fund. KaloCyte offers products and services including ErythroMer. KaloCyte operates in a competitive market with competitors including Satellite Bio, CorNeat Vision, Stratatech Corp, Morphocell Technologies and Haimai Medical, among others.
- Headquarter St. Louis, United States
- Founders Dipanjan Pan, Philip Spinella, Allan Doctor
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kalocyte, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.1 M (USD)
in 6 rounds
-
Latest Funding Round
$2.46 M (USD), Grant
Apr 15, 2024
-
Investors
HHS
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of KaloCyte
KaloCyte offers a comprehensive portfolio of products and services, including ErythroMer.
Dried substitute for red blood cells in trauma and emergencies.
People of KaloCyte
Unlock access to complete
Funding Insights of KaloCyte
KaloCyte has successfully raised a total of $1.1M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $2.46 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in KaloCyte
KaloCyte has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, NYBC Ventures and Maryland Momentum Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Investment funding is provided for University System of Maryland ventures.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for KaloCyte
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by KaloCyte
Investment portfolio details for KaloCyte
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - KaloCyte
Detailed financials for KaloCyte
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kalocyte Comparisons
Peer comparison for KaloCyte
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of KaloCyte
KaloCyte operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Satellite Bio, CorNeat Vision, Stratatech Corp, Morphocell Technologies and Haimai Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Proprietary implantable satellite organs are developed for cell therapy.
|
|
| Locked | Locked | Locked |
Nanotechnology-based artificial corneal implants are developed for ophthalmic use.
|
|
| Locked | Locked | Locked |
Cell-based skin substitutes are developed for therapeutic and research uses.
|
|
| Locked | Locked | Locked |
Engineered liver tissues are developed for liver disease treatments.
|
|
| Locked | Locked | Locked |
Tissue engineering technologies for cardiovascular regenerative surgeries are developed.
|
Detailed competitors of KaloCyte
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kalocyte
Complete news archive for KaloCyte
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about KaloCyte
KaloCyte was founded in 2016 and raised its 1st funding round 1 year after it was founded.
KaloCyte is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.
KaloCyte is a funded company, having raised a total of $1.1M across 6 funding rounds to date.
KaloCyte was founded in 2016 in St. Louis, United States, within the biotechnology sector. A nanotechnology platform is utilized to create ErythroMer, an immuno-silent nanoparticle designed to mimic red blood cell surfaces and facilitate oxygen binding and gas exchange. The technology is directed toward trauma care in low-resource environments, such as battlefields and remote areas, to address blood loss mortality. Operations focus on advancing this substitute for clinical applications.
KaloCyte's top competitors include Satellite Bio, Stratatech Corp and Morphocell Technologies.
KaloCyte offers ErythroMer.
KaloCyte has 3 investors. Key investors include HHS, NYBC Ventures, and Maryland Momentum Fund.